Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 2/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | ST6GAL1 | P15907 | 9/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891030 | 0.91 | P2RY2 (0.52) | P2RY2POLA1ST6GAL1TSHRGLA | |
| SCHEMBL1886860 | 0.87 | POLB (0.53) | P2RY2POLA1ST6GAL1P2RY4P2RY6 | |
| SCHEMBL1893832 | 0.87 | P2RY6 (0.53) | P2RY2P2RY4P2RY6 | |
| SCHEMBL1889866 | 0.85 | TSHR (0.55) | P2RY2POLA1ST6GAL1TSHRGLA | |
| SCHEMBL1890986 | 0.83 | TGM2 (0.61) | — | |
| SCHEMBL1894008 | 0.82 | DNPH1 (0.44) | P2RY6 | |
| SCHEMBL1893133 | 0.82 | P2RY1 (0.59) | P2RY2 | |
| SCHEMBL1895916 | 0.78 | P2RY6 (0.55) | P2RY2P2RY4P2RY6 | |
| SCHEMBL1887781 | 0.78 | ST6GAL1 (0.57) | P2RY2POLA1ST6GAL1TSHRGLA | |
| SCHEMBL1891681 | 0.78 | POLB (0.55) | P2RY2POLA1P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242087-B2 | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-08-14 | — | — | US | disclosed |
| US-20110112046-A9 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-05-12 | — | — | US | disclosed |
| US-20100093656-A1 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112046-A9 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | MTAP, POLRMT, PNP | P2RY2 1009/4885POLA1 35/4885ST6GAL1 1792/4885 |
| US-20100093656-A1 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | MTAP, POLRMT, PNP | P2RY2 1009/4885POLA1 35/4885ST6GAL1 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.